30-day FRN

79348

Federal Register / Vol. 80, No. 244 / Monday, December 21, 2015 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents

Form name

Form 1: Demographic, Service Utilization, and Clinical Indicators Data ....................................................................
Form 2: Performance and System Outcome Benchmark
Data ..................................................................................
Total ..............................................................................

Jackie Painter,
Director, Division of the Executive Secretariat.
[FR Doc. 2015–31936 Filed 12–18–15; 8:45 am]
BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by emailing the
indicated licensing contact at the
National Heart, Lung, and Blood, Office
of Technology Transfer and
Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
mstockstill on DSK4VPTVN1PROD with NOTICES

SUMMARY:

Fluorescent Nanodiamonds as Fiducial
Markers for Microscopy
Description of Technology
The invention relates to fluorescent
nanodiamonds (FNDs) and their uses as
fiducial markers for microscopy. FNDs
are bright fluorescent probes that do not
blink or bleach and have broad

VerDate Sep<11>2014

17:38 Dec 18, 2015

Jkt 238001

Number of
responses per
respondent

56

425

23,800

56

1

56

425

23,800

56

........................

56

........................

47,600

• Fluorescent Microscopy
• Super-resolution microscopy
• Correlative imaging techniques
combing fluorescence microscopy
with electron, x-ray, or atomic force
microscopy imaging modalities
Competitive Advantages
Non-blinking, Non-bleaching
Chemically inert
Chemically and physically stable
Broad excitation
Longevity

Development Stage
• In vitro data

Frm 00047

Fmt 4703

Total burden
hours

1

Potential Commercial Applications

PO 00000

Average
burden per
response
(in hours)

56

fluorescence excitation and emission
peaks. The fluorescence intensity can be
readily controlled by the size of the
FND, the number of fluorescent centers
produced in the nanodiamonds, or in
situ through the application of a weak
magnetic field. The particular advantage
of the FND compositions of this
invention are that they are particularly
useful for extended imaging of a single
sample over time periods that can be as
long as a week or more. In an exemplary
embodiment, FNDs are immobilized in
a substrate that are coated with an inert
top coating, like silicon dioxide, or
transparent polymer (e.g. poly-L-lysine,
poly-L-arginine, or siloxanes).
Generally, any suitable methods known
for surface functionalization of the
substrate can be used to make the
composition. In another aspect of this
invention, the inventors designed
software for super-resolution imaging
correction method is employed to
precisely determine the position
coordinates of each of a set of FNDs in
a plurality of images by using Gaussian
fitting of the point spread function
comprises each of the FNDs in the
plurality of images. The calculated
correction is then used to displace each
image to align the coordinates of the
FNDs. The positions of the FNDs can be
tracked with sub-nanometer precision
and residual drift can be reduced to the
nanometer scale over hundreds of hours
of tracking.

•
•
•
•
•

Total
responses

Sfmt 4703

Inventors
• Keir Neuman, Ambika Bumb, Han
Wen, Jennifer Hong and Susanta
Sarkar (all of NHLBI)
• Chang Yi, Lawrence Samelson, Asit
Manna (all of NCI)
Intellectual Property: HHS Reference
No. E–217–2015/0–US–01
• US Provisional Patent Application 62/
262,058 filed December 2, 2015.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
[email protected].
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute seeks statements of capability
or interest from parties interested in
collaborative research to further develop
and evaluate metallic nanoparticle
vesicles for cancer phototherapy. For
collaboration opportunities, please
contact Vincent Kolesnitchenko, Ph.D.
at [email protected].
Dated: December 15, 2015.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2015–31890 Filed 12–18–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery
(NIAID)
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health, has submitted to the
Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on October 1, 2015,
80 FR 59168 and allowed 60-days for

SUMMARY:

E:\FR\FM\21DEN1.SGM

21DEN1

Federal Register / Vol. 80, No. 244 / Monday, December 21, 2015 / Notices
public comment. No public comments
were received. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Institute of Allergy and Infectious
Diseases (NIAID), National Institutes of
Health, may not conduct or sponsor,
and the respondent is not required to
respond to, an information collection
that has been extended, revised, or
implemented on or after October 1,
1995, unless it displays a currently valid
OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
DATES: Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection

plans and instruments, or request more
information on the proposed project,
contact: Ms. Dione Washington, Health
Science Policy Analyst, Office of
Strategic Planning, Initiative
Development and Analysis, 5601
Fishers Lane, Rockville, Maryland
20892, or call a non-toll-free number
240 669 2100 or Email your request,
including your address to
[email protected]. Formal
requests for additional plans and
instruments must be requested in
writing. Formal requests for additional
plans and instruments must be
requested in writing.
Proposed Collection: Generic
Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery (NIAID), 0925–0668,
Expiration Date 1/31/2016,
EXTENSION, National Institute of
Allergy and Infectious Diseases (NIAID).
Need and Use of Information
Collection: There are no changes being
requested for this submission. The
proposed information collection activity
provides a means to garner qualitative
customer and stakeholder feedback in
an efficient, timely manner, in

79349

accordance with the Administration’s
commitment to improving service
delivery. By qualitative feedback we
mean information that provides useful
insights on perceptions and opinions,
but are not statistical surveys that yield
quantitative results that can be
generalized to the population of study.
This feedback will provide information
about the NIAID’s customer or
stakeholder perceptions, experiences
and expectations, provide an early
warning of issues with service, or focus
attention on areas where
communication, training or changes in
operations might improve delivery of
products or services. These collections
will allow for ongoing, collaborative and
actionable communications between the
NIAID and its customers and
stakeholders. It will also allow feedback
to contribute directly to the
improvement of program management.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
16,100.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Type of collection

Annual frequency
per response

Hours per
response

Total hours

Estimated Annual Reporting Burden
Customer satisfaction surveys .................................................
In-Depth Interviews (IDIs) or Small Discussion Groups ..........
Individual Brief Interviews ........................................................
Focus Groups ..........................................................................
Pilot testing surveys .................................................................
Conferences and Training Pre- and Post-surveys ..................
Website or Software Usability Tests .......................................

25,000
500
200
1,000
200
1,000
100

1
1
1
1
1
1
1

30/60
90/60
15/60
2
30/60
30/60
2

12,500
750
50
2,000
100
500
200

Total ..................................................................................

28,000

..............................

..............................

16,100

Dated: December 15, 2015.
Brandie Taylor Bumgardner,
Project Clearance Liaison, NIAID, NIH.
[FR Doc. 2015–31986 Filed 12–18–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

mstockstill on DSK4VPTVN1PROD with NOTICES

Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on

VerDate Sep<11>2014

17:38 Dec 18, 2015

Jkt 238001

proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)

PO 00000

Frm 00048

Fmt 4703

Sfmt 4703

ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Community Support
Evaluation (CSE)—New
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Mental Health
Services (CMHS), is requesting
clearance for the new data collection
associated with the CSE. The CSE is a
multicomponent evaluation of two
SAMHSA programs—Behavioral Health
Treatment Court Collaborative (BHTCC)
and Transforming Lives through
Supported Employment (SE). SE intends
to promote recovery for individuals
with serious mental illness, substance

E:\FR\FM\21DEN1.SGM

21DEN1